Genmab A/S (NASDAQ:GMAB) Shares Sold by Blue Trust Inc.

Blue Trust Inc. trimmed its stake in shares of Genmab A/S (NASDAQ:GMAB) by 36.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,747 shares of the company’s stock after selling 1,568 shares during the quarter. Blue Trust Inc.’s holdings in Genmab A/S were worth $57,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in GMAB. Two Sigma Advisers LP boosted its stake in Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after purchasing an additional 280,900 shares during the period. Natixis Advisors LLC boosted its position in shares of Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after buying an additional 47,437 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Genmab A/S by 229.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock worth $1,033,000 after buying an additional 34,652 shares during the period. FMR LLC grew its holdings in Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in Genmab A/S during the 3rd quarter valued at $709,000. Institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on GMAB shares. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $22.96 on Wednesday. The firm has a 50 day simple moving average of $20.83 and a 200 day simple moving average of $22.84. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88. The company has a market cap of $15.19 billion, a PE ratio of 13.20, a price-to-earnings-growth ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.